← Browse by Condition
Medical Condition

recurrent vaginal carcinoma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1

ClinicalMetric tracks all active clinical trials for recurrent vaginal carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — recurrent vaginal carcinoma Clinical Trials

How many clinical trials are currently recruiting for recurrent vaginal carcinoma?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for recurrent vaginal carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for recurrent vaginal carcinoma?
recurrent vaginal carcinoma research spans Phase 1 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a recurrent vaginal carcinoma clinical trial?
Eligibility criteria for recurrent vaginal carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Top Sponsors
M.D. Anderson Cancer Center 1 trial

Recruiting Clinical Trials

NCT03968406 Phase 1
Recruiting
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Enrollment
24 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →

Related Conditions

malignant female reproductive system neoplasm (1) recurrent cervical carcinoma (1) recurrent endometrial carcinoma (1) recurrent fallopian tube carcinoma (1) recurrent ovarian carcinoma (1) recurrent primary peritoneal carcinoma (1) stage iv cervical cancer ajcc v8 (1) stage iv fallopian tube cancer ajcc v8 (1) stage iv ovarian cancer ajcc v8 (1) stage iv primary peritoneal cancer ajcc v8 (1) stage iv uterine corpus cancer ajcc v8 (1) stage iv vaginal cancer ajcc v8 (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology